Intravenous Tirofiban After Tenecteplase in Acute Ischemic Stroke

Among patients with acute ischemic stroke without large or medium vessel occlusion or cardioembolic source, does intravenous tirofiban after an insufficient response to intravenous tenecteplase improve functional outcomes?In this randomized trial of 359 patients, tirofiban significantly increased the proportion of patients with an excellent outcome (defined as a score of 0 or 1 on the modified Rankin Scale) at 90 days compared with placebo (63.8% vs 52.2%, respectively).These findings suggest a potential benefit of adjunctive intravenous tirofiban after intravenous tenecteplase in this specific patient population and warrant further investigation.

Corresponding Authors: Guoyong Zeng, MD, Department of Neurology, The Affiliated Ganzhou Hospital of Nanchang University (Ganzhou People’s Hospital), No. 16 Meiguan Rd, Zhanggong District, Ganzhou 341000, China (hsyygy@163.com); Zhongming Qiu, MD, Department of Neurology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, No. 107 Yan Jiang Xi Rd, Guangzhou 510120, China (qiuzhongmingdoctor@163.com).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.